Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Zynerba Pharmaceuticals, Inc. (ZYNE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.5602+0.0255 (+4.77%)
At close: 01:00PM EST
0.5509 -0.01 (-1.66%)
After hours: 04:31PM EST
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in 22q11.2 Deletion Syndrome

    DEVON, Pa., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the European Commission (EC) has granted orphan drug designation to cannabidiol, the active ingredient in its transdermal gel, Zygel™, for the treatment of 22q11.2 deletion syndrome (22q). “We are pleased to have been granted orphan drug designation in the U.S. a

  • GlobeNewswire

    Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights

    Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 $55.9 million in cash and cash equivalents at September 30, 2022; Cash runway into first quarter 2024 DEVON, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today reported

  • GlobeNewswire

    Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22q11.2 Deletion Syndrome

    DEVON, Pa., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the U.S. Patent and Trademark Office has issued Patent No. 11,458,109, titled “Treatment of 22q11.2 Deletion Syndrome With Cannabidiol,” which includes claims directed to methods of treating one or more behavioral symptoms of 22q11.2 deletion syndrome with cannab

Advertisement
Advertisement